Mary M Zutter, Kenneth J Bloom, Liang Cheng, Ian S Hagemann, Jill H Kaufman, Alyssa M Krasinskas, Alexander J Lazar, Debra G B Leonard, Neal I Lindeman, Ann M Moyer, Marina N Nikiforova, Jan A Nowak, John D Pfeifer, Antonia R Sepulveda, Joseph E Willis, Sophia L Yohe1. 1. From the Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee (Dr Zutter); the Department of Pathology, Clarient Diagnostic Services, Aliso Viejo, California (Dr Bloom); the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis (Dr Cheng); the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Hagemann and Pfeifer); Surveys, College of American Pathologists, Northfield, Illinois (Dr Kaufman); the Department of Pathology, Emory University, Atlanta, Georgia (Dr Krasinskas); the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Lazar); the Department of Pathology and Laboratory Medicine, Fletcher Allen Health Care, Burlington, Vermont (Dr Leonard); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Lindeman); the Department of Pathology, Mayo Clinic, Rochester, Minnesota (Dr Moyer); Molecular and Genomic Pathology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Nikiforova); the Department of Pathology, NorthShore University Health System, Evanston, Illinois (Dr Nowak); the Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York (Dr Sepulveda); the Department of Pathology, Case Medical Center/Case Western Reserve University, Cleveland, Ohio (Dr Willis); and the Department of Molecular Pathology and Hematopathology, University of Minnesota, Minneapolis (Dr Yohe).
Abstract
CONTEXT: Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. OBJECTIVE: To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. DESIGN: The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. RESULTS: The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. CONCLUSIONS: The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.
CONTEXT: Genomic sequencing for cancer is offered by commercial for-profit laboratories, independent laboratory networks, and laboratories in academic medical centers and integrated health networks. The variability among the tests has created a complex, confusing environment. OBJECTIVE: To address the complexity, the Personalized Health Care (PHC) Committee of the College of American Pathologists proposed the development of a cancer genomics resource list (CGRL). The goal of this resource was to assist the laboratory pathology and clinical oncology communities. DESIGN: The PHC Committee established a working group in 2012 to address this goal. The group consisted of site-specific experts in cancer genetic sequencing. The group identified current next-generation sequencing (NGS)-based cancer tests and compiled them into a usable resource. The genes were annotated by the working group. The annotation process drew on published knowledge, including public databases and the medical literature. RESULTS: The compiled list includes NGS panels offered by 19 laboratories or vendors, accompanied by annotations. The list has 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels. In addition, tests for 393 genes were offered by only 1 or 2 institutions. Table 1 provides an example of gene mutations offered for breast cancer genomic testing with the annotation as it appears in the CGRL 2014. CONCLUSIONS: The final product, referred to as the Cancer Genomics Resource List 2014, is available as supplemental digital content.
Authors: Herve Tiriac; Juan Carlos Bucobo; Demetrios Tzimas; Suman Grewel; Joseph F Lacomb; Leahana M Rowehl; Satish Nagula; Maoxin Wu; Joseph Kim; Aaron Sasson; Shivakumar Vignesh; Laura Martello; Maria Munoz-Sagastibelza; Jonathan Somma; David A Tuveson; Ellen Li; Jonathan M Buscaglia Journal: Gastrointest Endosc Date: 2018-01-09 Impact factor: 9.427
Authors: Monica M Bertagnolli; Susan M Blaney; Charles D Blanke; Walter J Curran; Janet Dancey; Robert S Mannel; Peter J O'Dwyer; Mitchell D Schnall; Norman Wolmark Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Shuko Harada; Rebecca Arend; Qian Dai; Jessica A Levesque; Thomas S Winokur; Rongjun Guo; Martin J Heslin; Lisle Nabell; L Burt Nabors; Nita A Limdi; Kevin A Roth; Edward E Partridge; Gene P Siegal; Eddy S Yang Journal: Oncotarget Date: 2017-06-14
Authors: James C Willey; Tom B Morrison; Bradley Austermiller; Erin L Crawford; Daniel J Craig; Thomas M Blomquist; Wendell D Jones; Aminah Wali; Jennifer S Lococo; Nathan Haseley; Todd A Richmond; Natalia Novoradovskaya; Rebecca Kusko; Guangchun Chen; Quan-Zhen Li; Donald J Johann; Ira W Deveson; Timothy R Mercer; Leihong Wu; Joshua Xu Journal: Cell Rep Methods Date: 2021-11-03
Authors: Michael G Zomnir; Lev Lipkin; Maciej Pacula; Enrique Dominguez Meneses; Allison MacLeay; Sekhar Duraisamy; Nishchal Nadhamuni; Saeed H Al Turki; Zongli Zheng; Miguel Rivera; Valentina Nardi; Dora Dias-Santagata; A John Iafrate; Long P Le; Jochen K Lennerz Journal: JCO Clin Cancer Inform Date: 2018-03-22